
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At‑Risk Individuals  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At‑Risk Individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Source</strong>: <em>Gastroenterology</em> 2025;168:267‑284  </li>
<li style="margin-left: 0px;"><strong>Topic</strong>: HBV reactivation (HBVr) risk assessment, antiviral prophylaxis, monitoring, screening  </li>
<li style="margin-left: 0px;"><strong>Author(s)</strong>: Faisal S. Ali et al.  </li>
</ul>
<details><summary><strong>1. Guideline Scope &amp; Methodology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Background: HBVr occurs when immune suppression lifts control of latent HBV in HBsAg‑positive or anti‑HBc‑positive/HBsAg‑negative patients.  </li>
<li style="margin-left: 0px;">Methods: GRADE framework used; systematic evidence review since 2014 guideline; Evidence‑to‑Decision (EtD) tables incorporated benefits, harms, values, costs, equity.  </li>
<li style="margin-left: 0px;">Panel: 7 clinicians (5 hepatologists), 2 GRADE methodologists; conflicts disclosed and managed per AGA policy.  </li>
</ul>
</div></details>
<details><summary><strong>2. Core Recommendations (Risk‑Based Management)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 High‑Risk Individuals (&gt;10% baseline HBVr) – Strong Recommendation (moderate certainty)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Antiviral prophylaxis <strong>strongly recommended</strong> over monitoring alone.  </li>
<li style="margin-left: 0px;">Prophylaxis must start <em>before</em> immunosuppressive exposure and continue ≥6 months after therapy cessation (≥12 months for B‑cell–depleting agents).  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Moderate‑Risk Individuals (1%–10% baseline HBVr) – Conditional Recommendation (moderate certainty)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Antiviral prophylaxis <strong>suggested</strong>; patients may opt for active monitoring if they value avoiding long‑term antiviral use and cost.  </li>
<li style="margin-left: 0px;">Monitoring: HBV DNA + ALT every 1–3 months during exposure and after discontinuation.  </li>
</ul>
</div></details>
<details><summary><strong>2.3 Low‑Risk Individuals (&lt;1% baseline HBVr) – Conditional Recommendation (moderate certainty)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Monitoring alone</strong> suggested; antiviral prophylaxis optional for patients preferring maximal safety.  </li>
<li style="margin-left: 0px;">Monitoring schedule identical to moderate‑risk group.  </li>
</ul>
</div></details>
<details><summary><strong>2.4 Universal HBV Testing – Strong Recommendation (moderate certainty)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Test all adults ≥18 y (CDC guidance): HBsAg, anti‑HBs, total anti‑HBc.  </li>
<li style="margin-left: 0px;">No risk‑stratified screening needed; serology guides subsequent risk categorization.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Risk Stratification by Immunosuppressive Exposure <em>(selected agents)</em>  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Exposure</th>
<th>Baseline HBVr if <strong>HBsAg‑positive</strong></th>
<th>Baseline HBVr if <strong>anti‑HBc‑positive/HBsAg‑negative</strong></th>
</tr></thead>
<tbody>
<tr>
<td>B‑cell–depleting (rituximab, ofatumumab)</td>
<td><strong>High</strong> (&gt;10%)</td>
<td><strong>High</strong></td>
</tr>
<tr>
<td>Anthracyclines (doxorubicin, epirubicin)</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Anti‑TNF (infliximab, adalimumab)</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>TKIs (imatinib, sunitinib)</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>CAR‑T cell therapy</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Cytokine/Integrin inhibitors (ustekinumab, secukinumab)</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Anti‑IL6 (tocilizumab)</td>
<td>High</td>
<td>Low (imprecision)</td>
</tr>
<tr>
<td>JAK inhibitors (tofacitinib, baricitinib)</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>ICIs (nivolumab, pembrolizumab, ipilimumab)</td>
<td>Moderate</td>
<td>&lt;0.1% (very low)</td>
</tr>
<tr>
<td>Corticosteroids – moderate/high dose ≥10 mg pred‑equiv ≥4 wks</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Corticosteroids – low dose &lt;10 mg pred‑equiv ≤4 wks</td>
<td>Moderate</td>
<td>Low</td>
</tr>
<tr>
<td>TACE (transarterial chemoembolization)</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Methotrexate / 6‑MP / Azathioprine</td>
<td>Low</td>
<td>Low (conditional)</td>
</tr>
<tr>
<td>Vedolizumab (gut‑specific anti‑α4β7)</td>
<td>Insufficient data – case report only</td>
<td>—</td>
</tr>
</tbody>
</table>
<p><em>Risk categories derived from pooled RCTs/observational studies; where evidence sparse, biological plausibility and expert consensus applied.</em></p>
</div></details>
<details><summary><strong>4. Antiviral Prophylaxis Details  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Preferred agents: <strong>high barrier to resistance</strong> (entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide).  </li>
<li style="margin-left: 0px;">Duration: Minimum 6 months post‑exposure; extend to 12 months for B‑cell–depleting regimens.  </li>
<li style="margin-left: 0px;">Efficacy: Pooled RR = 0.18 (95% CI 0.11‑0.30) → <strong>82 % relative reduction</strong> in HBVr; absolute risk reduction varies with baseline (e.g., 410 fewer cases/1000 at 50 % baseline).  </li>
<li style="margin-left: 0px;">Safety: Minor renal/bone effects with TDF; TAF comparable safety profile; overall adverse‑event RR ≈ 1.08 (95% CI 0.47‑2.49).  </li>
</ul>
</div></details>
<details><summary><strong>5. Monitoring Strategy Without Prophylaxis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Frequency</strong>: HBV DNA and ALT every <em>1–3 months</em> while on immunosuppressive therapy; continue same interval for at least 6 months after exposure ends.  </li>
<li style="margin-left: 0px;"><strong>Trigger for Rescue Therapy</strong>: Detectable HBV‑DNA rise ≥10‑fold from baseline OR new HBsAg appearance → initiate antiviral treatment promptly.  </li>
<li style="margin-left: 0px;">Evidence: No RCTs directly comparing monitoring vs prophylaxis in low‑risk groups; conditional recommendation based on patient preference and feasibility.  </li>
</ul>
</div></details>
<details><summary><strong>6. Screening Implementation &amp; Interpretation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Initial Testing</strong>: Perform <em>simultaneous</em> HBsAg, anti‑HBs, total anti‑HBc*.  </li>
<li style="margin-left: 0px;"><strong>Serologic Algorithms</strong>:  </li>
<li style="margin-left: 20px;">HBsAg + → classify as <strong>HBsAg‑positive</strong>; assign exposure‑specific risk (high/moderate).  </li>
<li style="margin-left: 20px;">HBsAg‑negative &amp; anti‑HBc + → <em>resolved infection</em>; use anti‑HBc status for baseline risk.  </li>
<li style="margin-left: 20px;">Anti‑HBs ≥ 10 mIU/mL alone → indicates immunity, no prophylaxis needed unless other high‑risk exposure present.  </li>
<li style="margin-left: 0px;"><strong>Viral Load Testing</strong>: If HBsAg + or anti‑HBc +, obtain quantitative HBV DNA before starting immunosuppression; repeat per monitoring schedule.  </li>
</ul>
</div></details>
<details><summary><strong>7. Duration of Prophylaxis &amp; Post‑Exposure Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">RCTs comparing longer (12 mo) vs shorter (6 mo) continuation after exposure showed <strong>no significant difference</strong> in HBVr (RR = 0.99, 95% CI 0.76‑1.28).  </li>
<li style="margin-left: 0px;">Panel conclusion: Continue prophylaxis ≥6 months; extend to 12 months for agents with documented delayed reactivation (e.g., rituximab, other B‑cell depleters).  </li>
<li style="margin-left: 0px;"><strong>Case Example</strong>: Entecavir prophylaxis stopped at 6 mo after rituximab → HBVr observed &gt;12 mo in several case reports; supports extended duration.  </li>
</ul>
</div></details>
<details><summary><strong>8. Cost‑Effectiveness &amp; Health‑Equity Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No published CEAs for low‑ or moderate‑risk categories; one Japanese CEA (baseline risk = 6%) yielded ICER ≈ US$132,048/QALY → <strong>not cost‑effective</strong> at US willingness‑to‑pay threshold. Adjusting HBVr probability in prophylaxis arm to 1.1% (reflecting 82 % RR reduction) would lower ICER into acceptable range.  </li>
<li style="margin-left: 0px;">Antiviral drugs covered by most insurers; out‑of‑pocket costs may impede adherence for some patients → consider patient assistance programs.  </li>
<li style="margin-left: 0px;">Equity: No specific disparities identified in evidence review; universal screening aligns with CDC equity goals.  </li>
</ul>
</div></details>
<details><summary><strong>9. Knowledge Gaps &amp; Research Priorities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Baseline Risk Data</strong>: Need large, prospective cohorts reporting HBV serology and standardized HBVr definitions across emerging agents (e.g., newer TKIs, bispecific antibodies).  </li>
<li style="margin-left: 0px;"><strong>Corticosteroid Dose‑Response</strong>: Precise quantitative relationship between cumulative prednisone equivalents and HBVr remains uncertain.  </li>
<li style="margin-left: 0px;"><strong>Cost‑Effectiveness Analyses</strong>: Formal CEAs for each risk tier (low, moderate, high) required to inform policy.  </li>
<li style="margin-left: 0px;"><strong>Gut‑Specific Anti‑Integrin Therapy</strong>: Insufficient evidence for vedolizumab; registry data needed before risk categorization.  </li>
<li style="margin-left: 0px;"><strong>Anti‑HBs Protective Role</strong>: Pooled RCT anti‑HBs + rituximab subgroup showed baseline HBVr 6.6% (95% CI 5.8‑14.4%); panel concluded anti‑HBs status should <em>not</em> dictate prophylaxis decisions.  </li>
</ul>
</div></details>
<details><summary><strong>5. Outcomes of Antiviral Prophylaxis vs Monitoring  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">HBVr (critical): RR = 0.18 (95% CI 0.11‑0.30); absolute risk ↓ by <strong>Δ ≈ baseline × RR</strong> (e.g., 410 fewer/1000 at 50 % baseline).  </li>
<li style="margin-left: 0px;">Hepatitis flare from HBVr: pooled RR = 0.22 (95% CI 0.10‑0.50) → <strong>78 % relative reduction</strong>; absolute benefit mirrors reactivation risk tier.  </li>
<li style="margin-left: 0px;">Chemotherapy interruption: pooled RR = 0.31 (95% CI 0.05‑1.84); very low certainty, CI crosses both low‑ and high‑risk thresholds → effect considered imprecise.  </li>
</ul>
</div></details>
<details><summary><strong>6. Safety &amp; Harms of Antiviral Prophylaxis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Tenofovir disoproxil fumarate (TDF): possible ↑ renal creatinine, ↓ bone mineral density; overall impact <em>trivial</em>.  </li>
<li style="margin-left: 0px;">Tenofovir alafenamide (TAF): no significant renal or bone effects vs TDF.  </li>
<li style="margin-left: 0px;">Tenofovir‑related adverse events: out‑of‑pocket costs may act as barrier for some patients → shared decision making required.  </li>
</ul>
</div></details>
<details><summary><strong>7. Implementation Considerations &amp; Clinical Decision Support  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Strong recommendation assumes <strong>high‑barrier antivirals</strong>; start <em>before</em> risk‑imposing therapy, continue ≥6 mo after exposure.  </li>
<li style="margin-left: 0px;">For B‑cell–depleting regimens, extend prophylaxis to ≥12 months post‑therapy because delayed HBVr cases reported up to 18 months.  </li>
<li style="margin-left: 0px;">Monitoring alone assumes reliable follow‑up; must ensure patient adherence to 1‑to‑3‑month HBV DNA + ALT checks.  </li>
</ul>
</div></details>
<details><summary><strong>8. Equity, Cost‑Effectiveness &amp; Limitations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Equity: No health‑disparities issues identified in the EtD search; universal testing supports equitable care delivery.  </li>
<li style="margin-left: 0px;">Cost‑effectiveness: Current models (Fujita et al.) suggest prophylaxis not cost‑effective for low‑risk exposures (ICER ≈ US$132k/QALY &gt; US$45k threshold). Adjusted HBVr probabilities could improve ICER for high‑risk cases.  </li>
<li style="margin-left: 0px;">Limitations: Imprecise baseline risk estimates for several drug classes (anti‑IL6, anti‑IL6, JAK inhibitors in HBsAg‑positive cohorts); moderate‑risk categorization sometimes based on class effect rather than drug‑specific data.  </li>
</ul>
</div></details>
<details><summary><strong>9. Evidence Summary Tables (Key Outcomes)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>HBVr</strong>: 879 participants (12 RCTs), certainty ⨁⨁⨁/C, RR = 0.18 (95% CI 0.11‑0.30).  </li>
<li style="margin-left: 0px;"><strong>HBV flare</strong>: 624 participants (9 RCTs), certainty ⨁⨁⨁/C, RR = 0.22 (95% CI 0.10‑0.50).  </li>
<li style="margin-left: 0px;"><strong>Chemotherapy interruption</strong>: 124 participants (2 RCTs), very low certainty; pooled RR = 0.31 (95% CI 0.05‑1.84).  </li>
<li style="margin-left: 0px;"><strong>Adverse events of antivirals</strong>: 141 participants (2 RCTs), low certainty; pooled RR ≈ 1.08 (95% CI 0.47‑2.49).  </li>
</ul>
</div></details>
<details><summary><strong>10. Practical Clinical Decision Flowchart <em>(textual description)</em>  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Identify at‑risk patient</strong> → obtain HBsAg, anti‑HBc, anti‑HBs per universal testing recommendation.</p>
<p>2. <strong>Determine exposure risk</strong> using Table 6 (exposures &amp; serologic status).</p>
<p>3. <strong>Assign risk category</strong>: high (&gt;10 %), moderate (1%–10 %), low (&lt;1 %).</p>
<p>4. <strong>Apply recommendation</strong>:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;">High → antiviral prophylaxis <em>strongly</em>; start before exposure, continue ≥6 mo post‑therapy (≥12 mo for rituximab/ofatumumab).  </li>
<li style="margin-left: 30px;">Moderate → antiviral prophylaxis <em>conditional</em>; if declined, implement monitoring every 1–3 months (HBV DNA + ALT).  </li>
<li style="margin-left: 30px;">Low → monitoring alone <em>conditional</em>; same interval as moderate risk.  </li>
</ul>
</div></details>
<details><summary><strong>11. Limitations of Current Evidence  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Baseline‑risk estimates for many newer agents derived from small observational cohorts; imprecision led to downgrading certainty (e.g., anti‑IL6, JAK inhibitors in HBsAg‑negative patients).  </li>
<li style="margin-left: 0px;">No direct RCTs evaluating prophylaxis vs monitoring for several moderate‑risk exposures (e.g., TKIs, cytokine/integrin inhibitors); recommendations rely on pooled class effects and expert consensus.  </li>
<li style="margin-left: 0px;">Lack of cost‑effectiveness data across all risk tiers; only one CEA (moderate‑risk exposure) identified, limiting policy modeling.  </li>
</ul>
</div></details>
<details><summary><strong>12. Future Updates &amp; Maintenance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Guideline scheduled for revision in <strong>5 years</strong> (≈2029).  </li>
<li style="margin-left: 0px;">Panel recommends establishing a <em>living registry</em> of HBV serologies and reactivation events linked to novel immunotherapies; periodic meta‑analyses to refine baseline risk estimates.  </li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
